Noni fruit phenolic‐rich extract ameliorated non‐alcoholic fatty liver disease through regulating gut microbiota and bile acids profiling by targeting FXR – FGF15 signaling
Journal of the Science of Food and Agriculture · 15.01.2027 · 107 (1) · 914-926
DOI: 10.1002/jsfa.71032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Science of Food and Agriculture, online erschienen am 01.09.2026. Verfasst von Huixian Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Food Science and Engineering, Key Laboratory of Food Nutrition and Functional Food of Hainan Province, Collaborative Innovation Center of O…. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Non-alcoholic Fatty Liver Disease, Bile Acids and Salts, Receptors, Cytoplasmic and Nuclear. Die Arbeit nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND Non‐alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease globally, covering a spectrum from simple hepatic steatosis to steatohepatitis. With limited pharmacological interventions available, there is growing interest in natural products for NAFLD prevention and management. The farnesoid X receptor (FXR)–fibroblast growth factor 15 (FGF15) signaling pathway plays a pivotal role in regulating bile acid (BA) and lipid metabolism, and its dysregulation is closely linked to NAFLD progression. RESULTS Noni fruit phenolic‐rich extract (NFE) treatment ameliorated high‐fat diet (HFD)‐induced increases in body weight and lipid accumulation in both serum and hepatic tissues, accompanied by reduced serum aspartate aminotransferase and alanine aminotransferase activities, indicating improved hepatic function and reduced liver injury. Moreover, NFE intervention modulated the expression of key components of the FXR–FGF15 signaling pathway, leading to downregulation of hepatic CYP7A1 and subsequent modulation of BA and lipid metabolism. Notably, NFE intervention can modulate the gut microbiota and its metabolic functions, thereby sustaining BA homeostasis through feedback regulation of the FXR–FGF15 pathway. CONCLUSION In summary, NFE intervention alleviates high‐fat diet (HFD)‐induced NAFLD by modulating the FXR–FGF15 pathway, regulating bile acid metabolism, and reshaping gut microbiota. These results support the potential application of NFE as a nutritional intervention for NAFLD. © 2026 Society of Chemical Industry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Food Science and Engineering, Key Laboratory of Food Nutrition and Functional Food of Hainan Province, Collaborative Innovation Center of One Health, Hainan University, Haikou, China.
- Hainan Institute of Grain and Oil Science, Qionghai, China.
ORCID-Profile: Ruimin Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, H., Yang, D., Huang, Y., Liu, X., Liu, Y., Ma, Z., & Wang, R. (2027). Noni fruit phenolic‐rich extract ameliorated non‐alcoholic fatty liver disease through regulating gut microbiota and bile acids profiling by targeting FXR – FGF15 signaling. Journal of the Science of Food and Agriculture, 107(1), 914-926. https://doi.org/10.1002/jsfa.71032
Vancouver
Wang H, Yang D, Huang Y, Liu X, Liu Y, Ma Z, et al. Noni fruit phenolic‐rich extract ameliorated non‐alcoholic fatty liver disease through regulating gut microbiota and bile acids profiling by targeting FXR – FGF15 signaling. Journal of the Science of Food and Agriculture. 2027;107(1):914-926. doi:10.1002/jsfa.71032
BibTeX
@article{Wang2027,
author = {Wang, Huixian and Yang, Derui and Huang, Yi and Liu, Xinhui and Liu, Yunlan and Ma, Zewei and Wang, Ruimin},
title = {Noni fruit phenolic‐rich extract ameliorated non‐alcoholic fatty liver disease through regulating gut microbiota and bile acids profiling by targeting FXR – FGF15 signaling},
journal = {Journal of the Science of Food and Agriculture},
year = {2027},
volume = {107},
number = {1},
pages = {914--926},
doi = {10.1002/jsfa.71032}
}
EUVIMED